GLPwatch
MASH (metabolic dysfunction-associated steatohepatitis)
Approved indication
Last updated 2026-07-12 06:04 UTCResearch on semaglutide in the context of MASH (metabolic dysfunction-associated steatohepatitis) includes studies on its effects in mouse models of NAFLD (nonalcoholic fatty liver disease) and evaluations of its safety profile, as well as discussions on its potential mechanisms in MASLD (metabolic dysfunction-associated steatotic liver disease) treatment.
AI summary of the sources below.
Approved GLP-1 drugs (0)
No GLP-1 drug is FDA-approved for mash (metabolic dysfunction-associated steatohepatitis) in our data. Any research below reflects investigational or off-label study.
Research (50)
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
- EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
- Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
- Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
- An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
- Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.
- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.
- Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
- GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy.
- EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
- Recent updates on GLP-1 agonists: Current advancements & challenges.
- GLP-1 receptor agonists: a review of head-to-head clinical studies.
- Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
- Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.
- Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
- Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.
Common questions
- Which GLP-1 drugs are FDA-approved for MASH (metabolic dysfunction-associated steatohepatitis)?
- No GLP-1 drug is currently FDA-approved for mash (metabolic dysfunction-associated steatohepatitis); any use would be off-label or investigational.
- Is there research on GLP-1 drugs for MASH (metabolic dysfunction-associated steatohepatitis)?
- GLPwatch tracks 560 research papers on GLP-1 drugs and mash (metabolic dysfunction-associated steatohepatitis). This research is investigational and does not imply FDA approval.